AI healthcare is booming, and Anthropic is getting in on the action.
Following OpenAI’s launch of a healthcare product last week, AI startup Anthropic has quickly followed suit by entering the medical field.
According to Bloomberg on Monday, the $350 billion-valued company announced on Sunday the launch of HIPAA-compliant Claude medical services, enabling hospitals, medical institutions, and consumers to process protected health data. This highlights the fierce competition among Silicon Valley tech giants for this lucrative market.
Anthropic’s new medical features include integrations with scientific databases, enhanced capabilities for biological research, and the ability for users to export health data from apps such as Apple Health and Function Health. The company pledges not to use medical user data to train its models, and all medical responses are cited from authoritative publications like PubMed and NPI Registry.
A few days earlier, competitor OpenAI had just released ChatGPT Health, allowing users to securely connect to medical records and health apps. OpenAI’s data shows that over 230 million people consult health-related issues on its platform each week, underscoring the vast demand of the healthcare market. The consecutive launches from both companies reflect the urgency AI firms feel to establish themselves in the medical field to boost sales and demonstrate the extensive value of AI.
Competition in this sector is intense. Anthropic not only faces direct competition from OpenAI but must also contend with traditional tech providers and emerging startups focused on drug discovery, medical documentation, and patient record analysis.
Product Positioning: Empowerment, not Replacement
Anthropic’s Chief Product Officer and Instagram co-founder Mike Krieger stated that healthcare is one of the economic fields where AI can have the biggest impact—provided the right regulatory and data measures are in place. The new tool aims to “empower people to gain more knowledge, both from their own data and interactions with healthcare providers.”
OpenAI’s ChatGPT Health similarly emphasizes an assistive role. The product is not intended for diagnosis or treatment, nor for replacing medical care, but rather to help users manage everyday health concerns and provide more relevant responses by integrating users’ own health information.
Early Clients Show Results
Anthropic has made initial progress with healthcare institutions. According to the company, Banner Health—one of the largest nonprofit healthcare systems in the U.S.—has over 22,000 clinical providers using Claude, with 85% reporting faster work speed and higher accuracy. The company is also collaborating with clients such as Novo Nordisk and Stanford Health Care.
Founded in 2021 by former OpenAI employees, Anthropic positions itself as a trustworthy and safety-focused AI developer. Its software is especially popular among engineers for automating coding processes. The company’s CEO, Dario Amodei, has a background in biophysics, providing a professional foundation for its entry into healthcare.
Challenges in Privacy and Security
AI’s handling of sensitive personal data and providing advice for high-risk health matters brings new privacy and security challenges. Anthropic emphasizes that its medical responses include citations from authoritative sources like PubMed and NPI Registry to ensure clinicians have greater confidence in the results. The company states clearly it will not use medical user data to train its models.
According to media reports, Anthropic is currently in fundraising talks at a $350 billion valuation. The deployment in healthcare will be a key battleground for the AI startup to prove its commercial value and broad applicability of its technology.
Risk Disclaimer and Liability ClauseThe market entails risks; investment should be undertaken cautiously. This article does not constitute individual investment advice, nor does it take into account specific investment objectives, financial situations, or needs of any given user. Users should carefully consider whether any opinions, views, or conclusions in this article are appropriate to their particular circumstances. Investment based on this article is at your own risk.